Keywords: centocor, cnto, impresses, psoriasis, study, usa-based, subsidiary

Centocor's CNTO 1275 impresses in psoriasis study

Article | 19 February 2007

Print This

USA-based Centocor, a subsidiary of global health care major Johnson & Johnson, says that the results of a Phase II trial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in